Skip to main content

FDA Approvals

Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma

FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer

FDA Approvals, Leukemia, Oncology

Oral Onureg First Drug Approved for Adults with AML in Remission

Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow

Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

FDA Approvals, Lung Cancer, Oncology

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

FDA Approvals, Lung Cancer, Oncology

Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

FDA Approvals, Prostate Cancer

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

Page 10 of 20
Results 91 - 100 of 200